美国退伍军人冠状动脉旁路移植术后心脏保护性降糖药物的处方趋势
该研究分析2016至2019年全国退伍军人事务部数据库,评估2型糖尿病合并冠状动脉旁路移植术(CABG)患者中SGLT2i与GLP-1RA的处方趋势及相关因素。5,109例患者中SGLT2i、GLP-1RA及两者联用的处方比例分别为10.4%、6.8%、1.8%,总体使用率低,SGLT2i使用多于GLP-1RA。
要点
- CABG术后2型糖尿病患者中SGLT2i、GLP-1RA及两者联用处方比例分别为10.4%、6.8%、1.8%。
- SGLT2i季度处方率从2016Q1的1.6%升至2019Q4的33%,GLP-1RA从0.8%升至11.2%。
- 合并血管疾病或肾脏疾病者SGLT2i使用可能性较低,肥胖与GLP-1RA使用相关。
核心结论
- 美国2型糖尿病CABG术后退伍军人中SGLT2i或GLP-1RA总体使用率低,SGLT2i使用多于GLP-1RA。
研究设计与样本
- 分析2016至2019年全国退伍军人事务部(VA)数据库,报告CABG术后SGLT2i或GLP-1RA处方趋势及相关因素。
- 共纳入5,109例在40家VA医疗中心接受手术的患者。
主要发现
- 5,109例中525例(10.4%)处方SGLT2i,352例(6.8%)处方GLP-1RA,91例(1.8%)两者联用。
- SGLT2i季度处方率从2016Q1的1.6%升至2019Q4的33%,GLP-1RA从2016Q1的0.8%升至2019Q4的11.2%。
- 合并血管疾病者SGLT2i使用可能性较低(OR 0.75,95%CI 0.75, 0.94),合并肾脏疾病者亦较低(OR 0.72,95%CI 0.58, 0.88)。
- 肥胖与GLP-1RA使用相关(OR 1.91,95%CI 1.50, 2.46)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with type 2 diabetes undergoing coronary artery bypass grafting (CABG) are at risk for cardiovascular events. Sodium-glucose cotransporter 2 receptor inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) are effective cardioprotective agents; however, their prescription among CABG patients is uncertain. The aims of this study were 1) to evaluate the overall use of SGLT2i/GLP-1RA after CABG and explore longitudinal trends and 2) to examine patient-related factors associated with the use of SGLT2i or GLP-1RA. RESEARCH DESIGN AND METHODS: We analyzed the nationwide Veterans Affairs (VA) database (2016-2019) to report trends and factors associated with SGLT2i or GLP-1RA prescription after CABG. RESULTS: Among 5,109 patients operated on at 40 different VA medical centers, 525 of 5,109 (10.4%), 352 of 5,109 (6.8%), and 91 of 5,109 (1.8%) were prescribed SGLT2i, GLP-1RA, and both, respectively. A substantial increase in the quarterly SGLT2i prescription rates (1.6% [first quarter of 2016 (2016Q1)], 33% [2019Q4]) was present but was lower for GLP-1RA (0.8% [2016Q1], 11.2% [2019Q4]). SGLT2i use was less likely with preexisting vascular disease (odd ratio [OR] 0.75, 95% CI 0.75, 0.94) or kidney disease (OR 0.72, 95% CI 0.58, 0.88), while GLP-1RA use was associated with obesity (OR 1.91, 95% CI 1.50, 2.46). CONCLUSIONS: The overall utilization of SGLT2i or GLP-1RA drugs in U.S. veterans with type 2 diabetes undergoing CABG is low, with SGLT2i preferred over GLP-1RA.
引用
- Deo SV, McAllister DA, Al-Kindi S, et al. Trends in Prescriptions of Cardioprotective Diabetic Agents After Coronary Artery Bypass Grafting Among U.S. Veterans. Diabetes Care. 2022. PMID: 36256925. doi:10.2337/dc22-0570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。